Nu Skin Enterprises (NYSE:NUS) Updates FY19 Earnings Guidance

Nu Skin Enterprises (NYSE:NUS) issued an update on its FY19 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $3.20-3.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.94. The company issued revenue guidance of $2.48-2.52 billion, compared to the consensus revenue estimate of $2.77 billion.Nu Skin Enterprises also updated its FY 2019 guidance to $3.20-3.35 EPS.

Nu Skin Enterprises stock traded up $1.48 during trading on Tuesday, reaching $45.51. The company had a trading volume of 409,975 shares, compared to its average volume of 653,478. Nu Skin Enterprises has a 12-month low of $43.57 and a 12-month high of $88.68. The business’s 50 day moving average price is $48.08. The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of 12.93, a price-to-earnings-growth ratio of 1.03 and a beta of 0.74. The company has a quick ratio of 1.10, a current ratio of 1.86 and a debt-to-equity ratio of 0.44.

Nu Skin Enterprises (NYSE:NUS) last released its earnings results on Tuesday, April 30th. The company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. Nu Skin Enterprises had a net margin of 4.82% and a return on equity of 26.81%. The firm had revenue of $623.60 million during the quarter, compared to the consensus estimate of $615.98 million. During the same period in the previous year, the firm earned $0.79 earnings per share. Nu Skin Enterprises’s revenue was up 1.2% compared to the same quarter last year. Equities analysts expect that Nu Skin Enterprises will post 3.92 earnings per share for the current year.

NUS has been the subject of several research reports. Bank of America decreased their price objective on shares of Canopy Growth from $80.00 to $75.00 and set a buy rating for the company in a research note on Wednesday, June 19th. Stifel Nicolaus set a $99.00 price objective on shares of C.H. Robinson Worldwide and gave the stock a hold rating in a research note on Monday, March 25th. ValuEngine upgraded shares of Valmont Industries from a sell rating to a hold rating in a research note on Friday. Deutsche Bank downgraded shares of Hilton Hotels from a buy rating to a hold rating and set a $92.60 price objective for the company. in a research note on Wednesday, May 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of Inflarx from a buy rating to a hold rating in a research note on Friday, May 3rd. Three research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. Nu Skin Enterprises currently has an average rating of Hold and a consensus target price of $73.13.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Read More: New Google Finance Tool and Screening Stocks

Earnings History and Estimates for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with's FREE daily email newsletter.